Studies have revealed a partial deficiency of growth hormone (GK) secr
etion in the elderly. Aging has a central effect on the GH secretion a
nd probably a peripheral effect on insulin-like growth factor 1 (IGF-1
) or somatomedin C through changes in body composition. Simultaneously
therapeutic efficiency of recombinant GH was confirmed in adults with
GH deficiency. These notions have led to some controlled trials of GH
treatment in elderly. Further studies of GH replacement are needed, e
xamining issues such as dosage, tolerance (still inadequate) and effic
acy before the widespread use of GH or IGH-F1 in the elderly is advoca
ted.